A Phase 3 interventional study of Lenalidomide 5 mg and Lenalidomide 10 mg in Myelodysplastic Syndromes, sponsored by Celgene Corporation. Completed at 38 sites in 9 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-04-14.
Sponsored by Celgene Corporation (part of Bristol-Myers Squibb) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing lenalidomide in Myelodysplastic Syndromes — none open to participants now, none under way, none of them phase 3. Lenalidomide · Myelodysplastic Syndromes.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, this one is the 3rd largest by enrollment of the 43 interventional ones that give a count, is one of 3 that started in 2005, is one of 3 in phase 3, and was the 4th registered.
1,997 studies on the registry are indexed under Myelodysplastic Syndromes; 323 are open to participants now.
Browse Myelodysplastic Syndromes studies →None of the 44 studies testing lenalidomide in Myelodysplastic Syndromes is open now. The open studies under Myelodysplastic Syndromes, anywhere →
Lenalidomide: first FDA approval 2005 (REVLIMID), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 264 Myelodysplastic Syndromes studies recruiting now, 167 (63%) set no upper age limit and 70 (27%) stop at 75 or younger; 57 take children under 18; 17 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 31 · Phase 3 3
First in 2002; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 205 is above the median of 40 across 1,611 interventional studies indexed under Myelodysplastic Syndromes.
Median enrollment 32 across the 43 interventional studies. Of the 38 that completed or were terminated, 21 (55%) have results posted.
This tab as a report to print or save as PDF → With an account.
9 of 44 have an industry lead sponsor. The 10 most frequent:
This study is registered under Celgene Corporation, one of the names counted as Bristol-Myers Squibb. Under that name alone:
Celgene Corporation is the lead sponsor of 52 studies on the registry; none are open to participants now.
75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb: 4 open now, 9 under way, 5 of them phase 3. Of 63 finished, 20 (32%) have results posted.
Among the 75 studies in Myelodysplastic Syndromes by Bristol-Myers Squibb, this one is the 13th largest by enrollment of the 46 interventional ones that give a count, is one of 5 that started in 2005, is one of 11 in phase 3, and was the 8th registered.
Bristol-Myers Squibb’s Myelodysplastic Syndromes studies by the year they started, since 2001.
None of the studies under way reaches primary completion within a year.
Among the 44 studies testing lenalidomide in Myelodysplastic Syndromes, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Bristol-Myers Squibb’s 75 in Myelodysplastic Syndromes:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to compare 2 doses (10 mg and 5 mg) of lenalidomide to that of placebo in subjects with red blood cell (RBC) transfusion-dependent low- or intermediate-1-risk IPSS MDS associated with a deletion (del) 5q[31] cytogenetic abnormality. Study participants were randomized to one of the two treatment groups or to placebo and took the study drug for 16 weeks. At this timepoint, participants were evaluated for erythroid response. If participants did not achieve at least a minor erythroid response, they were discontinued from the Double-Blind phase and entered into the Open-Label phase. All erythroid responders at Week 16 were to continue in the Double-Blind phase for up to 52 weeks. For participants that were still responding at the end of Double-Blind phase, they could then rollover into the Open-Label phase for an additional two years. Participants could remain on study for up to a total of 3 years. All participants who discontinued from the study were followed every 4 months for overall survival and progression to acute myeloid leukemia (AML).
MDS-004 was a multicenter, randomized, double-blind, placebo-controlled, 3-arm study of 2 doses of lenalidomide versus placebo administered to RBC transfusion-dependent adults with low- or intermediate-1 risk MDS associated with a del 5q[31] cytogentetic abnormality. Potential participants that had a del 5q[31] cytogenetic abnormality plus other additional cytogenetic abnormalities were also eligible for enrollment. Transfusion-dependent anemia was defined as documentation that a participant with anemia due to MDS did not have any consecutive 56 days (8 weeks) that were RBC transfusion free during at least the 112 days (16 weeks) prior to Day 1 of the Pre-Randomization Phase.
This study was conducted in three phases:
Potentially protocol-eligible participants entered the Pre-Randomization Phase and were evaluated for the inclusion and exclusion criteria for the Double-Blind Treatment Phase. The Pre-Randomization Phase was not to last for more than 56 days (8 weeks). When the participant's baseline RBC transfusion requirement was calculated, and it had been determined that all eligibility criteria had been met, the participant could be randomized for treatment in the Double-Blind Treatment Phase at the time of their next RBC transfusion. This RBC transfusion had to occur within 56 days of the participant's last previous RBC transfusion.
Participants meeting eligibility criteria were randomized (1:1:1 ratio) to receive either lenalidomide 10 mg/day on days 1-21, lenalidomide 5 mg/day on days 1-28, or placebo on days 1-28; all on a 28-day cycle. Randomization was performed using a validated interactive voice response system. Participants were stratified according to karyotype (IPSS karyotype score: 0 vs > 0; i.e., isolated del 5q[31] vs del 5q[31] plus ≥ 1 additional cytogenetic abnormality). A complete blood count (CBC), serum or plasma ferritin, and EPO levels were measured to determine baseline levels.
Participants who achieved at least a minor erythroid response (i.e. 50% decrease in transfusion requirements) by week 16 could continue treatment in the Double-Blind phase for up to 52 weeks, unless there was evidence of erythroid relapse, disease progression, or unacceptable toxicity. Those who did not achieve at least a minor erythroid response by week 16 were discontinued from the Double-Blind phase for lack of therapeutic efficacy, and unblinded and were potentially eligible for Open-Label treatment. All participants who completed the double-blind treatment phase (the first 52 weeks of the trial) without disease progression or erythroid relapse were unblinded and entered the Open-Label extension phase at their current lenalidomide dose. Participants in the placebo or lenalidomide 5 mg arms who failed to achieve at least a minor erythroid response by week 16 or who had an erythroid relapse could cross over to lenalidomide 5 mg or 10 mg, respectively, in the Open-Label Extension phase.
Lenalidomide treatment could be continued in the Open-label Extension phase for up to 3 years (156 weeks) of total study participation. Participants with disease progression at any time and participants in the lenalidomide 10 mg group who did not achieve at least a minor erythroid response by week 16 were withdrawn from the study and were ineligible for Open-Label treatment.
Serial measurements for efficacy and safety were performed every 28 days. In addition, CBCs were monitored weekly for the first 8 weeks, every 2 weeks for the next 8 weeks, and every 4 weeks thereafter. Bone marrow aspirate (BMA) and standard cytogenetic studies were performed at baseline, weeks 12, week 24, and every 24 weeks thereafter and when clinically indicated for assessment of disease progression. BMAs were submitted for central pathology review and sent to a central cytogenetics laboratory for processing and review. All participants were followed for overall survival (OS) and progression to acute myeloid leukemia (AML).
Lenalidomide or placebo dosing was reduced for dose-limiting toxicities according to the following dose reduction schedule:
Lenalidomide 5 mg (starting dose)
Lenalidomide 10 mg (starting dose)
Participants who could not tolerate dose level -3 discontinued treatment. For grade 4 neutropenia, lenalidomide was required per protocol to be interrupted and resumed at a decreased dose level when the absolute neutrophil count (ANC) recovered to ≥ 500/μL. For grade 4 thrombocytopenia, lenalidomide was interrupted and then resumed at a decreased dose level when the platelet count recovered to: between ≥ 25,000/μL and \< 50,000/μL on at least 2 occasions for ≥ 7 days; or ≥ 50,000 at any time, respectively. Prophylactic and therapeutic use of granulocyte colony-stimulating factors (G-CSF) or granulocyte macrophage colony-stimulating factors (GM-CSF) was allowed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo matching to active study arms.
Drug: Placebo
Lenalidomide 5 mg daily 28/28 days
Drug: Lenalidomide 5 mg
Lenalidomide 10 mg daily 21/28 days
Drug: Lenalidomide 10 mg
Lenalidomide 5 mg daily 28/28 days
Also known as: Revlimid
Lenalidomide 10 mg daily 21/28 days
Also known as: Revlimid
Placebo, matching to active study drug arms
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days)
The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.
Time frame: Up to 52 weeks
Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days
Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.
Time frame: Up to 52 weeks
Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days
Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.
Time frame: up to 3 years
Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days
For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.
Time frame: Baseline, up to 52 weeks
Participants' Response in Platelet Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period
The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of \<100,000/mm\^3 as an absolute increase of ≥30,000/mm\^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm\^3 but less than 30,000/mm\^3.
Time frame: up to 52 weeks
Participants' Response in Absolute Neutrophil Counts as Defined by the International MDS Working Group (IWG 2000) During Double-blind Period
A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm\^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm\^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase \<500/mm\^3.
Time frame: up to week 52
Participants' Response Based on Bone Marrow Samples by the International MDS Working Group (IWG 2000) During Double-blind Period
The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) \<5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with \<5% blasts pretreatment with an on study blast increase of 50% which is now \>5% showed bone marrow progression.
Time frame: up to 52 weeks
Participants Showing Cytogenetic Response by the International MDS Working Group (IWG 2000) During Double-blind Period as Evaluated by Central Review
The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.
Time frame: up to 52 weeks
Participants Who Progressed to Acute Myeloid Leukemia (AML) During the Study
Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.
Time frame: up to 3 years
Kaplan Meier Estimates of Overall Survival by Randomized Group
Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.
Time frame: up to 3 years
Participant Count of Deaths During Double-blind and Open-label by Randomized Group
Count of participant deaths throughout the entire study and reported by the original treatment assignment.
Time frame: up to 3 years
Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12
The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL). In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.
Time frame: Baseline, Week 12
Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12
The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.
Time frame: Baseline, Week 12
Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12
The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.
Time frame: Baseline, Week 12
Summary of Participants Who Had Adverse Events (AE) During the Double-blind Period
Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.
Time frame: up to week 52
| Milestone | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Placebo Crossover to 5 mg Open-label Period |
|---|---|---|---|---|
| Started | 67 | 69 | 69 | 0 |
| Completed | 3 | 23 | 39 | 0 |
| Not completed | 64 | 46 | 30 | 0 |
| Withdrew: Lack of therapeutic effect | 59 | 35 | 19 | 0 |
| Withdrew: Adverse event | 2 | 7 | 4 | 0 |
| Withdrew: Withdrawal by subject | 2 | 1 | 3 | 0 |
| Withdrew: Death | 0 | 1 | 2 | 0 |
| Withdrew: Protocol violation | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 2 | 2 | 0 |
| Milestone | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Placebo Crossover to 5 mg Open-label Period |
|---|---|---|---|---|
| Started | 0 | 42 | 47 | 56 |
| Completed | 0 | 14 | 19 | 13 |
| Not completed | 0 | 28 | 28 | 43 |
| Withdrew: Lack of therapeutic effect | 0 | 19 | 19 | 31 |
| Withdrew: Adverse event | 0 | 6 | 5 | 6 |
| Withdrew: Withdrawal by subject | 0 | 2 | 2 | 2 |
| Withdrew: Death | 0 | 0 | 1 | 2 |
| Withdrew: Other | 0 | 1 | 1 | 2 |
The count of study participants who had no RBC transfusions for 26 consecutive weeks or more during the double-blind period.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for >= 26 Weeks (182 Days) | 3 | 20 | 23 |
Count of study participants who had no RBC transfusions during any 56 or more consecutive study days during the double-blind period.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Participants Who Achieved Red Blood Cell (RBC) Transfusion Independence for 56 Days | 4 | 24 | 25 |
Mean number of weeks that participants who achieved RBC transfusion independence for at least 182 days were able to maintain RBC transfusion independence. Both double-blind and open-label periods are included.
| Weeks | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Duration of Red Blood Cell (RBC) Transfusion Independence for Participants Who Became RBC Transfusion Independent for at Least 182 Days | 61.4 ± 10.93 | 107.7 ± 52.35 | 108.6 ± 40.63 |
For participants who became RBC transfusion independent for at least 182 days during the double-blind study period, the mean maximum change from baseline in hemoglobin is summarized.
| g/dL | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Maximum Change From Baseline in Hemoglobin During the Double-blind Period for Participants Who Became Red Blood Cell (RBC) Transfusion Independent for at Least 182 Days | 2.0 ± 0.61 | 5.5 ± 1.79 | 6.0 ± 1.97 |
The International MDS Working Group (IWG) defines a major platelet response for participants with a pre-treatment platelet count of \<100,000/mm\^3 as an absolute increase of ≥30,000/mm\^3 whereas a minor response is defined as a ≥50% increase in platelet count with a net increase greater than 10,000/mm\^3 but less than 30,000/mm\^3.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Major | 0 | 1 | 1 |
| Minor | 0 | 0 | 0 |
| None | 3 | 5 | 3 |
A major neutrophil response is defined by the International MDS Working Group (IWG) criteria as at least a 100% increase, or an absolute increase of ≥500/mm\^3 for participants with absolute neutrophil counts (ANC) of less than 1,500/mm\^3 before therapy, whichever is greater. A minor response for such participants is defined as an ANC increase of at least 100%, but absolute increase \<500/mm\^3.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Major | 1 | 3 | 2 |
| Minor | 0 | 0 | 1 |
| None | 9 | 15 | 14 |
The IWG criteria for bone marrow improvement: a complete remission is bone marrow sampling showing less than 5% myeloblasts with normal maturation of all cell lines, with no evidence for dysplasia. A partial remission is ≥ 50% decrease in blasts over pre-treatment. Bone marrow progression is a ≥ 50% increase in blasts that exceed the top range of the pretreatment percentile range: a) \<5% blasts b) 5-10% blasts c) 10-20% blasts d) 20-30% blasts. For example, a participant with \<5% blasts pretreatment with an on study blast increase of 50% which is now \>5% showed bone marrow progression.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Complete remission | 0 | 7 | 12 |
| Partial remission | 0 | 5 | 1 |
| Stable Disease | 37 | 35 | 33 |
| Progression | 3 | 4 | 3 |
The IWG criteria for evaluating cytogenetic response require a minimum of 20 baseline and post-baseline analyzable metaphases using conventional cytogenetic techniques. A major cytogenetic response is defined as no detectable cytogenetic abnormality if preexisting abnormality was present whereas a minor response requires ≥50% reduction in abnormal metaphases. Progression could be concluded based on as few as 3 metaphases if there were additional abnormalities. The best response is represented.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Major response | 0 | 5 | 10 |
| Minor response | 0 | 3 | 7 |
| Cytogenetic progression | 5 | 10 | 8 |
| Not evaluable/data not available | 10 | 10 | 1 |
Number of participants who progressed to acute myeloid leukemia during the study, summarized at three different timepoints: first 16 weeks of the double-blind study, week 52 of the double-blind study, and up to 36 months which includes the double-blind and open-label periods of the study. The counts are cumulative by timeframe.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Double-Blind (first 16 weeks) | 2 | 2 | 0 |
| Double-Blind (52 weeks) | 4 | 7 | 2 |
| Double-Blind + Open-Label | 21 | 16 | 15 |
Kaplan Meier estimate for median length of survival for study participants as they were randomized at the start of the study.
| Months | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Kaplan Meier Estimates of Overall Survival by Randomized Group | 42.4 (31.9 to NA) | NA (24.6 to NA) | 44.5 (35.5 to NA) |
Count of participant deaths throughout the entire study and reported by the original treatment assignment.
| Participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Participant Count of Deaths During Double-blind and Open-label by Randomized Group | 35 | 32 | 34 |
The Functional Assessment of Cancer Therapy-Anemia (FACT-An) questionnaire (Yellen, 1997) was used to assess health-related quality of life (HRQoL). In addition to general HRQoL, the FACT-An measures the impact of fatigue and other anemia-related symptoms on patient functioning. The overall score range for the FACT-An is 0-188. Higher scores indicate better HRQoL.
| units on a scale | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Change From Baseline in the Functional Assessment of Cancer Therapy-Anemia (FACT-An) Endpoints at Week 12 | -2.5 ± 18.50 | 5.9 ± 18.26 | 5.8 ± 23.17 |
The Trial Outcome Index-Anemia (TOI-An) composed of the physical and functional subscales of the FACT-G along with the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-An is 0-136. Higher scores indicate better HRQoL.
| units on a scale | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Change From Baseline in the Trial Outcome Index-Anemia (TOI-An) Endpoints at Week 12 | -1.1 ± 17.13 | 5.6 ± 15.56 | 4.9 ± 18.16 |
The Trial Outcome Index-Fatigue(TOI-F) composed of the physical and functional subscales of the FACT-G along with the fatigue items from the Anemia subscale was used to assess health-related quality of life (HRQoL). The overall score range for the TOI-F is 0-108. Higher scores indicate better HRQoL.
| units on a scale | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| Change From Baseline in the Trial Outcome Index-Fatigue (TOI-F) Endpoints at Week 12 | -0.8 ± 14.76 | 4.8 ± 14.21 | 3.9 ± 15.47 |
Counts of study participants who had adverse events (AEs) during the double-blind period by MedDRA System Organ Class (SOC) and preferred term. A participant with multiple occurrences of an adverse event within a category is counted only once in that category. Adverse events were evaluated by the investigator. The National Cancer Institute (NCI)'s Common Terminology Criteria for AEs (CTCAE) was used to grade AE severity. Severity grade 3= severe and undesirable AE. Severity grade 4= life-threatening or disabling AE.
| participants | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg |
|---|---|---|---|
| At least one AE | 64 | 69 | 69 |
| At least one AE related to study drug | 34 | 68 | 66 |
| At least one NCI CTCAE grade 3-4 AE | 29 | 62 | 65 |
| At least one related NCI CTCAE grade 3-4 AE | 13 | 61 | 61 |
| At least one serious AE | 14 | 31 | 32 |
| At least one serious AE related to study drug | 1 | 17 | 13 |
| An AE leading to discontinuation of study drug | 3 | 12 | 6 |
| An AE leading to dose reduction or interruption | 5 | 44 | 51 |
| Deaths within 30 days of last dose of study drug | 4 | 2 | 4 |
Collected over Placebo arm is limited to the double-blind period. Lenalidomide 5 mg and 10 mg treatment arms cover both double-blind and open-label periods. The Placebo Crossover to 5 mg Open-label Period arm is limited to the open-label period.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 14/67 (20.9%) | 64/67 (95.5%) |
| Lenalidomide 5 mg | — | 42/69 (60.9%) | 69/69 (100%) |
| Lenalidomide 10 mg | — | 42/69 (60.9%) | 69/69 (100%) |
| Placebo Crossover to 5 mg Open-label Period | — | 33/56 (58.9%) | 56/56 (100%) |
| Event | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Placebo Crossover to 5 mg Open-label Period |
|---|---|---|---|---|
| Acute Myeloid LeukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 2/67 | 8/69 | 8/69 | 5/56 |
| NeutropeniaBlood and lymphatic system disorders | 0/67 | 5/69 | 5/69 | 5/56 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/67 | 6/69 | 3/69 | 3/56 |
| PyrexiaGeneral disorders | 2/67 | 5/69 | 2/69 | 3/56 |
| PneumoniaInfections and infestations | 1/67 | 5/69 | 3/69 | 1/56 |
| Deep Vein ThrombosisVascular disorders | 1/67 | 1/69 | 4/69 | 3/56 |
| AnaemiaBlood and lymphatic system disorders | 0/67 | 4/69 | 1/69 | 1/56 |
| Cardiac FailureCardiac disorders | 0/67 | 2/69 | 1/69 | 3/56 |
| Febrile NeutropeniaBlood and lymphatic system disorders | 0/67 | 2/69 | 2/69 | 3/56 |
| Urinary Tract InfectionInfections and infestations | 0/67 | 3/69 | 1/69 | 0/56 |
| Event | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Placebo Crossover to 5 mg Open-label Period |
|---|---|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 12/67 | 55/69 | 57/69 | 45/56 |
| ThrombocytopeniaBlood and lymphatic system disorders | 2/67 | 38/69 | 36/69 | 26/56 |
| DiarrhoeaGastrointestinal disorders | 12/67 | 32/69 | 37/69 | 26/56 |
| NauseaGastrointestinal disorders | 6/67 | 16/69 | 21/69 | 11/56 |
| ConstipationGastrointestinal disorders | 5/67 | 18/69 | 19/69 | 17/56 |
| PruritusSkin and subcutaneous tissue disorders | 3/67 | 16/69 | 20/69 | 7/56 |
| RashSkin and subcutaneous tissue disorders | 1/67 | 18/69 | 12/69 | 8/56 |
| FatigueGeneral disorders | 5/67 | 17/69 | 17/69 | 11/56 |
| AnaemiaBlood and lymphatic system disorders | 6/67 | 10/69 | 6/69 | 13/56 |
| Muscle SpasmsMusculoskeletal and connective tissue disorders | 6/67 | 12/69 | 15/69 | 13/56 |
| Age Continuous(years) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| Median | 69.9 (39.0 to 85.0) | 66.0 (40.0 to 86.0) | 68.0 (36.0 to 84.0) | 68.0 (36.0 to 86.0) |
| Sex: Female, Male(Participants) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| Female | 54 | 53 | 49 | 156 |
| Male | 13 | 16 | 20 | 49 |
| Race/Ethnicity, Customized(participants) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| White | 66 | 67 | 69 | 202 |
| Other | 1 | 2 | 0 | 3 |
| 5q- (31-33) Chromosomal Abnormality(Participants) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| Yes | 63 | 64 | 64 | 191 |
| No | 1 | 2 | 1 | 4 |
| Missing | 3 | 3 | 4 | 10 |
| International Prognostic Scoring System (IPSS)(participants) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| Low risk (0) | 30 | 20 | 20 | 70 |
| Intermediate-1 (0.5 - 1.0) | 22 | 29 | 23 | 74 |
| Intermediate-2 (1.5 - 2.0) | 2 | 5 | 3 | 10 |
| High Risk (≥ 2.5) | 0 | 0 | 1 | 1 |
| Missing data | 13 | 15 | 22 | 50 |
| French-American-British (FAB) Classification(participants) | Placebo | Lenalidomide 5 mg | Lenalidomide 10 mg | Total |
|---|---|---|---|---|
| Refractory anemia (RA) | 37 | 38 | 32 | 107 |
| Refractory anemia with ringed sideroblasts (RARS) | 8 | 7 | 9 | 24 |
| Refractory anemia with excess blasts (RAEB) | 4 | 9 | 9 | 22 |
| Chronic myelomonocytic leukemia (CMML) | 1 | 2 | 0 | 3 |
| RAEB in transformation | 1 | 0 | 0 | 1 |
| Chronic myelogenous leukemia (CML) | 0 | 0 | 1 | 1 |
| Specimen not adequate from diagnosis | 12 | 11 | 17 | 40 |
| Other or missing | 4 | 2 | 1 | 7 |
The record gives a start of Jul 2005, a primary completion of Jun 2008 and a completion of Jun 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Mar 2011, 2 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Lenalidomide